2LBA - Opposing therapeutic efficacy of BET inhibitors is determined by cancer type-specific SPOP mutants
| Autor: | Janouskova, H., El Tekle, G., Udeshi, N., Ulbricht, A., Rinaldi, A., Civenni, G., Catapano, C., Peter, M., Carr, S., Garraway, L., Theurillat, J.P. |
|---|---|
| Zdroj: | In European Journal of Cancer December 2016 69 Supplement 1:S2-S2 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect